Biologics and Biosimilars Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1066949
  • May 2021
  • Pharmaceuticals
  • 136 Pages
The global Biologics and Biosimilars market research report provides complete study and detail analysis of the market. This study includes forecast analysis of the market which is based on global and regional level, whereas the research reports the provides forecast data from 2020-2028 and historic of 2018 and 2019. All the values are based on revenue USD Million. Moreover, the market research report describes various segments of the Biologics and Biosimilars market based on its types, applications and end-use industry. The applications of the market are explained in different industry verticals with reference to major countries across the globe. Along with this, the research report also covers all the major players that are operating in the global Biologics and Biosimilars market. These major players of the market are further studied and analyzed based on various parameters, such as annual market revenue, annual sales of the company, marketing strategy, historic growth and shipment volumes. Based on all the company’s insights, the market research analyst also suggests business strategy and marketing plans for improving the market position of existing participants of Biologics and Biosimilars market.
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered Pfizer Inc., Intas Pharmaceuticals Ltd., Biocon, Dr. Reddy\'s Laboratories Ltd., Sandoz International GmbH (Novartis division), CELLTRION INC., Amgen Inc., STADA Arzneimittel AG, Apotex Inc., Biogen
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Impact Analysis
The analysis of covid-19 is based on the impact of the current pandemic situation on market scenarios. This includes impact of covid-19 outbreak on overall revenue, market segments as well as regional market. The report also puts light on detailed impact analysis by taking into consideration all the government policies imposed during the pandemic situation, temporary shutdown of manufacturing units, current state of supply chain and distributors, and its future impacts on the growth of overall market. The market study will assist user to understand the global demand and impose strategic business plans to compete with the peers.

Apart from this, the market research report also covers drivers and restraints for the global Biologics and Biosimilars market and their impact on the demand and supply during the forecast period. Along with this, the research report also provides Biologics and Biosimilars market trends and opportunities that are based on regional and global level. Furthermore, the market research report also provides the major distributors and manufacturers that are operating in all the key region across the world. The researched data provided in the report is widely used by various industry players to strengthen their distribution channel and improve the geographical reach. In addition, the report also covers all the major players of the global Biologics and Biosimilars market and its key offerings and solutions. The report also provides recent mergers and acquisitions of these key players.

The data which is provided in the market research report is analyzed and evaluated with the help of various marketing tools, such as SWOT analysis, Poster’s Five Force analysis, PESTEL analysis, value chain analysis, player positioning analysis and market share analysis. Therefore, this analysis tools helps the analyst to evaluate the Biologics and Biosimilars market based on various parameters such as capital investments, impact of consumer’s preferences, economies of scale, manufacturing rights and patents, existing distribution channels, switching costs, government regulations and brand loyalty.

Major Key Players for Global Biologics and Biosimilars Market:
The Biologics and Biosimilars market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Pfizer Inc., Intas Pharmaceuticals Ltd., Biocon, Dr. Reddy\'s Laboratories Ltd., Sandoz International GmbH (Novartis division), CELLTRION INC., Amgen Inc., STADA Arzneimittel AG, Apotex Inc., Biogen

Biologics and Biosimilars Market Segment Analysis:
by
Recombinant Glycosylated Proteins
Recombinant Non-Glycosylated Proteins
Indication
Chronic Diseases
Oncology
Autoimmune Diseases
Infectious Diseases
Blood Disorders
Growth Hormone Deficiency
Other

Geographic Coverage for Biologics and Biosimilars Market:
The market research report on global Biologics and Biosimilars market offers complete analysis across various regions across the world. The Biologics and Biosimilars market is distributed into various regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The global leading market share as per the region is evaluated after considering Biologics and Biosimilars market revenue, sales, shares, recent developments, innovations and growth rates. This section of regional analysis provides widespread evaluation of the industry from various countries and regions.

North America Biologics and Biosimilars Market Value and Forecast
  • US
  • Canada
Europe Biologics and Biosimilars Market Value and Forecast
  • UK
  • Germany
  • France
  •  Rest of Europe
Asia Pacific Biologics and Biosimilars Market Value and Forecast
  • China
  • Japan
  • India
  • Rest of Asia Pacific
Latin America Biologics and Biosimilars Market Value and Forecast
  • Mexico
  • Brazil
  • Rest of Latin America
Middle East and Africa Biologics and Biosimilars Market Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa


Key highlights of the Biologics and Biosimilars market report:
  • The report provides key trends of the global Biologics and Biosimilars market
  • The report also covers consumer preferences and current industry growth
  • Key products or solutions offered by the main players in the Biologics and Biosimilars industry
  • The report covers all the recent developments of the Biologics and Biosimilars market and helps to provide current industry updates
  • The report covers a detailed look over the global Biologics and Biosimilars Industry and provides with significant actionable insights
  • The Biologics and Biosimilars market estimation from 2020-2028 and historical data for 2018 and 2019
  • The market study also provides data on changing market dynamics, market intelligence, current and future market trends
  • The report also analyses the microeconomic and macroeconomic factors that are affecting the global Biologics and Biosimilars market
  • In-depth analysis of the market’s competitive landscape and detailed information about the vendors
  • The report also offers key market drivers, restrains, trends and opportunities with present and future impact on the market
  • Detailed information about the major players or manufacturers of the global Biologics and Biosimilars market
  • Comprehensive analysis of the Biologics and Biosimilars market segments based on its types, applications and end-use industry
Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Biologics and Biosimilars market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Biologics and Biosimilars market for numerous purposes such as:

     1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

      2.  Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Biologics and Biosimilars market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Biologics and Biosimilars market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

      3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Biologics and Biosimilars market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • Pfizer Inc.
  • Intas Pharmaceuticals Ltd.
  • Biocon
  • Dr. Reddy's Laboratories Ltd.
  • Sandoz International GmbH (Novartis division)
  • CELLTRION INC.
  • Amgen Inc.
  • STADA Arzneimittel AG
  • Apotex Inc.
  • Biogen
  • Recombinant Glycosylated Proteins
  • Recombinant Non-Glycosylated Proteins
  • Chronic Diseases
  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Blood Disorders
  • Growth Hormone Deficiency
  • Other

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Biologics and Biosimilars Market Snapshot
          2.1.1. Global Biologics and Biosimilars Market By ,2019
               2.1.1.1.Recombinant Glycosylated Proteins
               2.1.1.2.Recombinant Non-Glycosylated Proteins
          2.1.2. Global Biologics and Biosimilars Market By Indication,2019
               2.1.2.1.Chronic Diseases
               2.1.2.2.Oncology
               2.1.2.3.Autoimmune Diseases
               2.1.2.4.Infectious Diseases
               2.1.2.5.Blood Disorders
               2.1.2.6.Growth Hormone Deficiency
               2.1.2.7.Other
          2.1.3. Global Biologics and Biosimilars Market By End-use,2019
          2.1.4. Global Biologics and Biosimilars Market By Geography,2019

3. Global Biologics and Biosimilars Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Biologics and Biosimilars Market Size (US$), By , 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By , 2019 vs.2028
          4.1.2. Attractive Investment Proposition By , 2020
     4.2. Global Biologics and Biosimilars Market Size (US$), By , 2018 – 2028

5. Global Biologics and Biosimilars Market Size (US$), By Indication, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Indication, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Indication, 2020
     5.2. Global Biologics and Biosimilars Market Size (US$), By Indication, 2018 – 2028

6. Global Biologics and Biosimilars Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Biologics and Biosimilars Market Size (US$), By End-use, 2018 – 2028

7. Global Biologics and Biosimilars Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Biologics and Biosimilars Market Analysis, 2018 – 2028 
          7.2.1. North America Biologics and Biosimilars Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Biologics and Biosimilars Market Size (US$), By , 2018 – 2028
          7.2.3. North America Biologics and Biosimilars Market Size (US$), By Indication, 2018 – 2028
          7.2.4. North America Biologics and Biosimilars Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Biologics and Biosimilars Market Analysis, 2018 – 2028 
          7.3.1.  Europe Biologics and Biosimilars Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Biologics and Biosimilars Market Size (US$), By , 2018 – 2028
          7.3.3. Europe Biologics and Biosimilars Market Size (US$), By Indication, 2018 – 2028
          7.3.4. Europe Biologics and Biosimilars Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Biologics and Biosimilars Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Biologics and Biosimilars Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Biologics and Biosimilars Market Size (US$), By , 2018 – 2028
          7.4.3. Asia Pacific Biologics and Biosimilars Market Size (US$), By Indication, 2018 – 2028
          7.4.4. Asia Pacific Biologics and Biosimilars Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Biologics and Biosimilars Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Biologics and Biosimilars Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Biologics and Biosimilars Market Size (US$), By , 2018 – 2028
          7.5.3. Latin America Biologics and Biosimilars Market Size (US$), By Indication, 2018 – 2028
          7.5.4. Latin America Biologics and Biosimilars Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Biologics and Biosimilars Market Analysis, 2018 – 2028 
          7.6.1.  MEA Biologics and Biosimilars Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Biologics and Biosimilars Market Size (US$), By , 2018 – 2028
          7.6.3. MEA Biologics and Biosimilars Market Size (US$), By Indication, 2018 – 2028
          7.6.4. MEA Biologics and Biosimilars Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Biologics and Biosimilars Providers
        8.4.1 Pfizer Inc.
                8.4.1.1 Business Description
                8.4.1.2 Pfizer Inc. Geographic Operations
                8.4.1.3 Pfizer Inc. Financial Information
                8.4.1.4 Pfizer Inc. Product Positions/Portfolio
                8.4.1.5 Pfizer Inc. Key Developments
        8.4.2 Intas Pharmaceuticals Ltd.
                8.4.2.1 Business Description
                8.4.2.2 Intas Pharmaceuticals Ltd. Geographic Operations
                8.4.2.3 Intas Pharmaceuticals Ltd. Financial Information
                8.4.2.4 Intas Pharmaceuticals Ltd. Product Positions/Portfolio
                8.4.2.5 Intas Pharmaceuticals Ltd. Key Developments
        8.4.3 Biocon
                8.4.3.1 Business Description
                8.4.3.2 Biocon Geographic Operations
                8.4.3.3 Biocon Financial Information
                8.4.3.4 Biocon Product Positions/Portfolio
                8.4.3.5 Biocon Key Developments
        8.4.4 Dr. Reddy's Laboratories Ltd.
                8.4.4.1 Business Description
                8.4.4.2 Dr. Reddy's Laboratories Ltd. Geographic Operations
                8.4.4.3 Dr. Reddy's Laboratories Ltd. Financial Information
                8.4.4.4 Dr. Reddy's Laboratories Ltd. Product Positions/Portfolio
                8.4.4.5 Dr. Reddy's Laboratories Ltd. Key Developments
        8.4.5 Sandoz International GmbH (Novartis division)
                8.4.5.1 Business Description
                8.4.5.2 Sandoz International GmbH (Novartis division) Geographic Operations
                8.4.5.3 Sandoz International GmbH (Novartis division) Financial Information
                8.4.5.4 Sandoz International GmbH (Novartis division) Product Positions/Portfolio
                8.4.5.5 Sandoz International GmbH (Novartis division) Key Developments
        8.4.6 CELLTRION INC.
                8.4.6.1 Business Description
                8.4.6.2 CELLTRION INC. Geographic Operations
                8.4.6.3 CELLTRION INC. Financial Information
                8.4.6.4 CELLTRION INC. Product Positions/Portfolio
                8.4.6.5 CELLTRION INC. Key Developments
        8.4.7 Amgen Inc.
                8.4.7.1 Business Description
                8.4.7.2 Amgen Inc. Geographic Operations
                8.4.7.3 Amgen Inc. Financial Information
                8.4.7.4 Amgen Inc. Product Positions/Portfolio
                8.4.7.5 Amgen Inc. Key Developments
        8.4.8 STADA Arzneimittel AG
                8.4.8.1 Business Description
                8.4.8.2 STADA Arzneimittel AG Geographic Operations
                8.4.8.3 STADA Arzneimittel AG Financial Information
                8.4.8.4 STADA Arzneimittel AG Product Positions/Portfolio
                8.4.8.5 STADA Arzneimittel AG Key Developments
        8.4.9 Apotex Inc.
                8.4.9.1 Business Description
                8.4.9.2 Apotex Inc. Geographic Operations
                8.4.9.3 Apotex Inc. Financial Information
                8.4.9.4 Apotex Inc. Product Positions/Portfolio
                8.4.9.5 Apotex Inc. Key Developments
        8.4.10 Biogen
                8.4.10.1 Business Description
                8.4.10.2 Biogen Geographic Operations
                8.4.10.3 Biogen Financial Information
                8.4.10.4 Biogen Product Positions/Portfolio
                8.4.10.5 Biogen Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Biologics and Biosimilars Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Biologics and Biosimilars Market Revenue, By , 2018 – 2028 (US$ Mn) 
TABLE 5 North America Biologics and Biosimilars Market Revenue, By Indication, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Biologics and Biosimilars Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Biologics and Biosimilars Market Revenue, By , 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Biologics and Biosimilars Market Revenue, By Indication, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Biologics and Biosimilars Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Biologics and Biosimilars Market Revenue, By , 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Biologics and Biosimilars Market Revenue, By Indication, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Biologics and Biosimilars Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Biologics and Biosimilars Market Revenue, By , 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Biologics and Biosimilars Market Revenue, By Indication, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Biologics and Biosimilars Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Biologics and Biosimilars Market Revenue, By , 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Biologics and Biosimilars Market Revenue, By Indication, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Biologics and Biosimilars Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Biologics and Biosimilars: Market Segmentation 
FIG. 2 Global Biologics and Biosimilars Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Biologics and Biosimilars Market, By , 2019 (US$ Mn) 
FIG. 5 Global Biologics and Biosimilars Market, By Indication, 2019 (US$ Mn) 
FIG. 6 Global Biologics and Biosimilars Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Biologics and Biosimilars Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Biologics and Biosimilars Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Biologics and Biosimilars Providers, 2019
FIG. 11 Global Biologics and Biosimilars Market Revenue Contribution, By , 2019 & 2028 (Value %) 
FIG. 12 Global Biologics and Biosimilars Market Revenue Contribution, By Indication, 2019 & 2028 (Value %) 
FIG. 13 Global Biologics and Biosimilars Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Biologics and Biosimilars Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Biologics and Biosimilars Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Biologics and Biosimilars Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Biologics and Biosimilars Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Biologics and Biosimilars Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Biologics and Biosimilars market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Biologics and Biosimilars Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Biologics and Biosimilars Market Value, By Segment1, 2018 – 2028
TABLE  North America Biologics and Biosimilars Market Value, By Segment2, 2018 – 2028
TABLE  North America Biologics and Biosimilars Market Value, By Country, 2018 – 2028
TABLE  Europe Biologics and Biosimilars Market Value, By Segment1, 2018 – 2028
TABLE  Europe Biologics and Biosimilars Market Value, By Segment2, 2018 – 2028
TABLE  Europe Biologics and Biosimilars Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Biologics and Biosimilars Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Biologics and Biosimilars Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Biologics and Biosimilars Market Value, By Country, 2018 – 2028
TABLE  Latin America Biologics and Biosimilars Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Biologics and Biosimilars Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Biologics and Biosimilars Market Value, By Country, 2018 – 2028
TABLE  MEA Biologics and Biosimilars Market Value, By Segment1, 2018 – 2028
TABLE  MEA Biologics and Biosimilars Market Value, By Segment2, 2018 – 2028
TABLE  MEA Biologics and Biosimilars Market Value, By Country, 2018 – 2028
TABLE  Pfizer Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Intas Pharmaceuticals Ltd.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Biocon: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Dr. Reddy's Laboratories Ltd.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Sandoz International GmbH (Novartis division): Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  CELLTRION INC.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Amgen Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  STADA Arzneimittel AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Apotex Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Biogen: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Biologics and Biosimilars Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Biologics and Biosimilars Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Biologics and Biosimilars Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Biologics and Biosimilars Market, By Geography, 2019 (US$ Mn)
FIG.  Global Biologics and Biosimilars Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Biologics and Biosimilars Providers, 2016
FIG.  Global Biologics and Biosimilars Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Recombinant Non-Glycosylated Proteins Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Biologics and Biosimilars Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Oncology Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Autoimmune Diseases Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Infectious Diseases Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Blood Disorders Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Growth Hormone Deficiency Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Other Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Biologics and Biosimilars Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Biologics and Biosimilars Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Biologics and Biosimilars Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Biologics and Biosimilars Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Biologics and Biosimilars Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Biologics and Biosimilars Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Biologics and Biosimilars Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Biologics and Biosimilars Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Biologics and Biosimilars Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Biologics and Biosimilars Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Biologics and Biosimilars Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Biologics and Biosimilars Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Biologics and Biosimilars Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Biologics and Biosimilars Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Biologics and Biosimilars Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Biologics and Biosimilars Market Value, 2018 – 2028, (US$ Mn)